The RV144 phase III clinical trial correlated lower HIV infection risk with binding of antibodies to linear V2, V3 and V1/V2 epitopes, together with IgG3 antibodies against the Env V1/V2 (23–25). This evidence concerns the gene ERVW-1 and HIV infectious disease.